Rivaroxaban in Pediatric Patients With DVT

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
Treatment of deep venous thrombotic events in children is based on data obtained inadults with little direct documentation of its efficacy and safety in children.Rivaroxaban is a direct oral anticoagulant which has been approved by FDA in 2021 for theuse in pediatric patients with venous thrombosis.In a randomized controlled trial we will study the safety and efficacy of rivaroxaban usein the pediatric population with acute deep venous thrombosis.
Epistemonikos ID: 31860768baa9cbfbeb3a76b0a31298631dfa38e7
First added on: Jun 02, 2026